Answers are grounded in this paper and cite their sources.
This study presents the epidemiology, resistance patterns, and clinical outcomes of Candidozyma auris fungemia in patients admitted to Aga Khan University Hospital, Karachi, Pakistan, from 2017 to 2024. Data was extracted from medical records using the hospital information system. Information was collected on comorbidities, prior antibiotics, antifungal or immunosuppressant use, ICU admission, presence of other multidrug-resistant organisms (MDROs), health care interventions and outcome. Adjusted Hazard Ratios (aHRs) with corresponding 95% confidence intervals (CIs) were calculated to quantify the independent effect of each factor on mortality. A total of 117 patients were included, with a median age of 52.0 years (IQR: 26.0–70.0), hospital stay of 7.0 days (IQR: 3.0–12.0), and ICU stay of 16 days (IQR: 8.0–26.0). Microbiological clearance in 4 days occurred in 66% (n=56). 83.8% (n=98) received antifungal therapy, with 39.8% (n=39) receiving early appropriate therapy and 25.2% (n=25) achieved source control within 48 hours. Prior antibiotic exposure was high (94.9%, n=111), and 31.6% (n=37) had received antifungal treatment. Overall mortality was 56.4% (n=66). Compared with pediatric patients, the hazard of in-hospital mortality was significantly higher among elderly patients aged ≥65 years (aHR 2.37, 95% CI 1.01–5.56; p=0.047), while adults aged 18–64 years also showed an increased hazard that did not reach statistical significance(aHR 2.08, 95% CI 0.94–4.59; p=0.069). A Pitt bacteremia score ≥4 was independently associated with a fourfold higher hazard of in-hospital mortality (aHR 4.00, 95% CI 1.23–12.95; p=0.020). C. auris fungemia was associated with high mortality, particularly among elderly patients. Severe illness, reflected by a Pitt bacteremia score ≥4, was independent predictors of mortality for C. auris fungemia patients. These findings emphasize the need for prompt recognition, early initiation of appropriate antifungal treatment, timely source control, and close monitoring of microbiological clearance to improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Tareen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: